6Z4 Stock Overview A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Crinetics Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Crinetics Pharmaceuticals Historical stock prices Current Share Price US$36.40 52 Week High US$57.00 52 Week Low US$33.40 Beta 0.60 1 Month Change -26.02% 3 Month Change -27.20% 1 Year Change 7.06% 3 Year Change 127.50% 5 Year Change 80.20% Change since IPO 81.91%
Recent News & Updates
Crinetics Announces Positive Topline Results from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (Cah) Jan 10
Crinetics Pharmaceuticals, Inc. Appoints Isabel Kalofonos as Chief Commercial Officer Dec 16
Crinetics Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly Dec 10
Third quarter 2024 earnings released: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023) Nov 13
Crinetics Pharmaceuticals, Inc. to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at the North American Neuroendocrine Tumor Society Annual Meeting Nov 13
Crinetics Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Oct 16 See more updates
Crinetics Announces Positive Topline Results from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (Cah) Jan 10
Crinetics Pharmaceuticals, Inc. Appoints Isabel Kalofonos as Chief Commercial Officer Dec 16
Crinetics Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly Dec 10
Third quarter 2024 earnings released: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023) Nov 13
Crinetics Pharmaceuticals, Inc. to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at the North American Neuroendocrine Tumor Society Annual Meeting Nov 13
Crinetics Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Oct 16 Crinetics Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $400 million. Oct 09
Crinetics Pharmaceuticals, Inc. Submits New Drug Application for Paltusotine for the Treatment of Acromegaly Sep 27
Second quarter 2024 earnings released: US$0.94 loss per share (vs US$0.94 loss in 2Q 2023) Aug 09 Crinetics Pharmaceuticals, Inc. Announces Marc Wilson Will Be Transitioning from His Role as Chief Financial Officer Aug 09
Crinetics Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 19 Crinetics Pharmaceuticals, Inc.(NasdaqGS:CRNX) dropped from Russell 2500 Value Index Crinetics Pharmaceuticals, Inc. Presents New Data At ENDO 2024 That Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
Crinetics Pharmaceuticals, Inc. Appoints Robert M. Cuddihy as Senior Vice President of Medical Affairs May 31
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts May 25
First quarter 2024 earnings released: US$0.93 loss per share (vs US$0.85 loss in 1Q 2023) May 11
Crinetics Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 09, 2024 May 03
Crinetics Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2024 Apr 28
Crinetics Pharmaceuticals, Inc. Announces Positive Topline Results from PATHFNDR-2, Second of Two Phase 3 Studies Evaluating Efficacy and Safety of Oral, Once-Daily Investigational Paltusotine for Treatment of Acromegaly Mar 19
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome Mar 13
Full year 2023 earnings released: US$3.69 loss per share (vs US$3.15 loss in FY 2022) Feb 29 Crinetics Pharmaceuticals, Inc. announced that it expects to receive $350.000028 million in funding from a group of investors Feb 29
Crinetics Pharmaceuticals, Inc. announced that it expects to receive $350.000028 million in funding from a group of investors Feb 28
Crinetics Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 16
Crinetics Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 15
Crinetics Pharmaceuticals, Inc. Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome Dec 19
Third quarter 2023 earnings released: US$1.01 loss per share (vs US$0.78 loss in 3Q 2022) Nov 08
New minor risk - Shareholder dilution Sep 13
Crinetics' Once-Daily Oral Paltusotine Achieves the Primary and All Secondary Endpoints in the Phase 3 Pathfr-1 Study Evaluating Treatment of Patients with Acromegaly Sep 12
New major risk - Revenue and earnings growth Aug 28
New minor risk - Shareholder dilution Aug 09
Second quarter 2023 earnings released: US$0.94 loss per share (vs US$0.81 loss in 2Q 2022) Aug 09
Founder recently sold €903k worth of stock Jul 16
Founder recently sold €952k worth of stock Jun 25
Crinetics Pharmaceuticals, Inc. Presents Efficacy, Safety and Patient-Reported Outcome Data At ENDO 2023 Jun 22
Chief Development Officer recently sold €121k worth of stock Apr 06
Crinetics Pharmaceuticals, Inc. Provides Update on Crn04777 Program Nov 29
High number of new directors Nov 16
Crinetics Pharmaceuticals, Inc. Completes Enrollment in Phase 3 PATHFNDR-1 Study Oct 14
Crinetics Pharmaceuticals, Inc Announces that Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism Oct 07
Crinetics Pharmaceuticals Appoints Dana Pizzuti as Chief Development Officer Oct 04
Crinetics Pharmaceuticals Announces New Long-Term Safety and Efficacy Data Presented with Paltusotine in Participants Living with Acromegaly Sep 07
High number of new and inexperienced directors Jun 01
Crinetics Pharmaceuticals, Inc. Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts May 26
High number of new and inexperienced directors May 02
Full year 2021 earnings released: US$2.80 loss per share (vs US$2.42 loss in FY 2020) Apr 01
Crinetics Pharmaceuticals, Inc. Reports Positive Top-Line Results from CRN04777 Phase 1 Study Multiple-Ascending Dose Cohorts Mar 31
Crinetics Pharmaceuticals Appoints James Hassard as Chief Commercial Officer Mar 03
Crinetics Pharmaceuticals to Presents Corporate and Clinical Update Jan 13
Crinetics Pharmaceuticals, Inc. to Unveil Its Parathyroid Hormone Receptor Antagonist Program At the American Society for Bone and Mineral Research Annual Meeting Sep 29
Crinetics Pharmaceuticals’ Oral ACTH Antagonist, CRN04894, Demonstrates Pharmacologic Proof-of-Concept with Dose-Dependent Cortisol Suppression in Single Ascending Dose Portion of Phase 1 Study Aug 12
Full year 2020 earnings released: US$2.42 loss per share (vs US$2.09 loss in FY 2019) Apr 02
Crinetics Pharmaceuticals, Inc. Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushing’s Disease (CRN04894) Advances into Phase 1 Study Feb 05
New 90-day high: €12.40 Feb 05
Crinetics Pharmaceuticals Advances Crn04777 for Congenital Hyperinsulinism into Phase 1 Study Feb 04
Founder recently bought €53k worth of stock Dec 05
Revenue in line with expectations Nov 08
New 90-day low: €10.80 Oct 29
Crinetics Pharmaceuticals Announces Phase 2 ACROBAT Edge Study with Paltusotine in Acromegaly Met Primary Endpoint Oct 27
New 90-day low: €11.50 Sep 25
Crinetics Pharmaceuticals, Inc. Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism Sep 22
Earnings released Aug 07
New 90-day low - €11.60 Aug 03 Shareholder Returns 6Z4 DE Biotechs DE Market 7D -4.7% 0.4% 1.9% 1Y 7.1% -6.5% 14.1%
See full shareholder returns
Return vs Market: 6Z4 underperformed the German Market which returned 12.9% over the past year.
Price Volatility Is 6Z4's price volatile compared to industry and market? 6Z4 volatility 6Z4 Average Weekly Movement 8.2% Biotechs Industry Average Movement 6.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.0% 10% least volatile stocks in DE Market 2.5%
Stable Share Price: 6Z4's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6Z4's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing’s disease.
Show more Crinetics Pharmaceuticals, Inc. Fundamentals Summary How do Crinetics Pharmaceuticals's earnings and revenue compare to its market cap? 6Z4 fundamental statistics Market cap €3.40b Earnings (TTM ) -€266.90m Revenue (TTM ) €997.86k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 6Z4 income statement (TTM ) Revenue US$1.04m Cost of Revenue US$50.64m Gross Profit -US$49.60m Other Expenses US$228.31m Earnings -US$277.91m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -3.00 Gross Margin -4,774.21% Net Profit Margin -26,747.83% Debt/Equity Ratio 0%
How did 6Z4 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/29 17:37 End of Day Share Price 2025/01/29 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Crinetics Pharmaceuticals, Inc. is covered by 17 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Brian Skorney Baird Joshua Schimmer Cantor Fitzgerald & Co. Charles Duncan Cantor Fitzgerald & Co.
Show 14 more analysts 
